Medicamen Biotech Limited has informed the Exchange about change in Management
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has informed the exchanges that two Independent Directors, Mr. Harish Pande (DIN: 01575625) and Mr. Arun Kumar (DIN: 07031730), have completed their term as Independent Directors effective February 13, 2026. Consequently, they have also stepped down from their roles as Chairman/Members of the Audit Committee, Nomination & Remuneration Committee, Stakeholders' Relationship Committee, Risk Management Committee, and CSR Committee. Mr. Sham Goel and Mr. Ashwani Kumar Sharma will continue as Chairman/Member of these committees, with Mr. Sham Goel also chairing the CSR Committee. The company also recalled that Mr. Sham Goel and Mr. Shaival Saurabh were appointed as Non-Executive Independent Directors in August 2025, with shareholder approval at the AGM in September 2025.
This is a routine governance event arising from the natural expiry of independent director tenures, with continuity already ensured through pre-existing appointees. No material impact on operations or shareholder value is expected, though investors may note the change in board committee composition.